Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

Álvarez, Claudio; Alonso-Muriel, Isabel; García, Gabriela; Crespo, Juana; Bellver, José; Simón, Carlos; Pellicer, António

doi:10.1093/humrep/dem315

Cited by 93 publications

(50 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However it was explored and found that women at risk for OHSS who had received this drug had fertilization, implantation and pregnancy rates comparable to those of controls, matched with respect to age, number and quality of the embryos replaced, embryonic stage at transfer and sperm quality. 29 Ongoing and full-term pregnancies were also similar in each group, and no major perinatal problems were detected. Cb2 administration in early pregnancy has not revealed to be harmful either, as published studies have reported employing it up to 7 mg per week, and the frequency of spontaneous and induced abortions and major congenital malformations were comparable with rates in the general population.…”

Section: Safety Profilementioning

confidence: 70%

See 1 more Smart Citation

VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status

Naredi

Talwar

Kharb

2014

Medical Journal Armed Forces India

View full text Add to dashboard Cite

Section: Safety Profilementioning

confidence: 70%

“…38,39 However Alvarez et al in their study have presented that endometrial angiogenesis was not greatly altered, by the dose of Cb2 employed since neither implantation nor the overall ART outcome was affected. 29 …”

mentioning

confidence: 99%

VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status

Naredi

Talwar

Kharb

2014

Medical Journal Armed Forces India

View full text Add to dashboard Cite

“…dosage or type of medications [9,10], administration of intravenous albumin [11,12], dopamine agonists [13,14] and avoidance of ET, and thus pregnancy, immediately after stimulation with freezing of embryos for subsequent use [12,[15][16][17][18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients

Sabatini

Wolkovich

Macklin

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate pregnancy rate (PR) and live birth rate (LBR) after freezing pronuclear (PN) embryos for two purposes: to reduce the risk of ovarian hyperstimulation syndrome (OHSS) and to bank embryos for cancer patients anticipating gametotoxic chemotherapy/radiotherapy. Methods Data from 3,621 consecutive IVF cycles were retrospectively analyzed. PN freezing was offered to patients at risk for OHSS and for those wishing to preserve fertility prior to cancer therapy. Primary outcomes evaluated were PR and LBR. Outcomes were compared to patients who underwent fresh embryo transfer (ET) in 2006. Results Sixty-six patients froze PN embryos. Thirty-eight were at risk for OHSS. The LBR was 34.3% after one transfer, and 51.4% after a mean of 1.4 transfers. Twenty-eight cancer patients froze embryos. The LBR was 16.7% after one transfer and 25.0% after a mean of 1.5 transfers. The LBR was 35.5% for patients who underwent fresh ET. Conclusion PN freezing with delayed ET is an effective tool for achieving pregnancy for patients at risk of OHSS and for cancer patients wishing to preserve fertility.

show abstract

“…In addition, cabergoline reduces the occurrence of moderate-severe OHSS with no relevant negative effects on the number of retrieved oocytes or implantation rates and clinical pregnancy, without deleterious impact on pregnancy outcome 47,48 . Moreover, evaluating the long-term eff ects of prophylactic treatment with cabergoline, no negative impact on live birth rates and miscarriage rates without increased rate of congenital malformations of the babies born has been observed 49,50 . Quinagolide used in a fi xed regimen of three oral doses (50, 100 and 200 μg/day), starting on the day of hCG and continued for 17-21 days, signifi cantly reduces the frequency of moderate/severe early OHSS (12% vs. 13% vs. 4%) as compared with placebo (23%), without compromising pregnancy or treatment outcome.…”

Section: Dopamine Agonistsmentioning

confidence: 99%

Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome

Kasum

Orešković

Franulić

et al. 2017

acc

View full text Add to dashboard Cite

SUMMARY -Th e purpose of this review is to analyze current medical strategies in the prevention of ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation for in vitro fertilization. Owing to contemporary preventive measures of OHSS, the incidence of moderate and severe forms of the syndrome varies between 0.18% and 1.40%. Although none of medical strategies is completely eff ective, there is high-quality evidence that replacing human chorionic gonadotropin (hCG) by gonadotropin-releasing hormone (GnRH) agonists after GnRH antagonists and moderate-quality evidence that GnRH antagonist protocols, dopamine agonists and mild protocols reduce the occurrence of OHSS. Among various GnRH agonists, buserelin 0.5 mg, triptorelin 0.2 mg and leuprolide acetate (0.5-4 mg) have been mostly utilized. Although GnRH trigger is currently regarded as the best tool for OHSS prevention, intensive luteal support with exogenous administration of estradiol and progesterone or low-dose hCG on the day of oocyte retrieval or on the day of GnRH agonist trigger are required to achieve optimal conception rates due to early luteolysis. Among currently available dopamine agonists, cabergoline, quinagolide and bromocriptine are the most common drugs that should be used for prevention of both early and late OHSS. Mild stimulation protocols off er attractive option in OHSS prevention with satisfactory pregnancy rates.

show abstract

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

Abstract: Administration of Cb2 in order to prevent OHSS is safe and does not appear to affect ART outcome.

Cited by 93 publications

References 45 publications

VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status

VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status

Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients

Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome

Contact Info

Product

Resources

About